More than 100 neuroendocrine tumor researchers and clinicians from 25 U.S. states and eight countries came together to share progress at the Neuroendocrine Tumor Research Foundation (NETRF) Annual Research Symposium on May 2-3, 2019 in Boston, MA, USA.
Physicians and scientists said some of the earliest objectives of NETRF were coming to fruition.
“Remarkable progress has been made in the last ten-plus years. It is truly extraordinary. It has gone from a question of whether it can be done to seeing it and being amazed at how well it can be done,” said Matthew Meyerson, MD, Dana-Farber Cancer Institute.
NETRF’s Board of Scientific Advisors, Evan Vosburgh, MD, said we are at a tipping point, moving from follower to leader, “I think we will now be informing other tumor types. It’s almost flipped.”
Presenters at the conference shared unpublished research in many areas. Presentations on laboratory models, immuno-oncology, and nuclear medicine sparked the most discussion.